CLRB

Cellectar Biosciences, Inc. (CLRB) - 2024 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2024. Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company developing cancer treatments using its proprietary Phospholipid Ether Drug Conjugate (PDC) platform. The company focuses on radioconjugate PDCs (PRCs) designed to deliver radioisotopes directly to cancer cells. As of December 31, 2024, the company had 11 full-time employees.

Key Financial Metrics

Note: The company has no revenue. The 2024 net loss includes a non-cash gain of $13.8 million from the change in fair value of warrants, partially offset by a $7.7 million warrant issuance expense.

Material Changes vs. Prior Period

• Financing Activity: Net cash proceeds from financing activities were approximately $61.4 million in 2024, primarily from the exercise of warrants, compared to $22.9 million in 2023. This significantly increased cash reserves from $9.6 million to $23.3 million.
• Operating Expenses: Total operating expenses increased by $12.8 million (33%). General and Administrative (G&A) expenses surged by $13.9 million (119%) due to investments in commercialization infrastructure and personnel. Research and Development (R&D) expenses decreased slightly by $1.1 million (4%), driven by lower clinical project costs, partially offset by higher manufacturing costs.
• Other Income/Expense: The company reported $7.3 million in other income in 2024, a reversal from a $3.9 million expense in 2023. This shift was driven by a $13.8 million gain on the valuation of warrants and increased interest income ($1.2 million vs. $0.4 million).
• Workforce Reduction: In December 2024, the company implemented a workforce reduction impacting approximately 60% of employees, with a total expense charge of $1.5 million.

Guidance, Outlook, Risks, and Unusual Items

Clinical Pipeline Progress:

• Iopofosine (CLR 131): The pivotal CLOVER-WaM Phase 2 study in Waldenstrom's macroglobulinemia (WM) met its primary endpoint with a 61% Major Response Rate (MRR). The company is pursuing strategic options for further development and commercialization following FDA communications regarding a confirmatory study.
• Future Programs: CLR 121225 (Actinium-225) and CLR 121125 (Iodine-125) are prepared to enter Phase 1 clinical trials in the first half of 2025.

Liquidity and Going Concern:

Management has raised substantial doubt about the company's ability to continue as a going concern. As of the issuance date, available liquidity was limited to approximately $14.9 million of unrestricted cash. Management believes current cash is adequate to fund operations only into the fourth quarter of 2025. The company plans to secure additional capital via equity/debt sales or strategic transactions.

Key Risks:

• Nasdaq Listing: On January 30, 2025, the company received a deficiency letter from Nasdaq for failing to maintain the $1.00 minimum closing bid price for 30 consecutive days. The company has until July 29, 2025, to regain compliance.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, leading to the restatement of financial statements for 2022 and 2023. Remediation efforts are ongoing.
• Capital Requirements: Continued dependence on external financing is required to fund R&D and operations.

Investor Verification Checklist

• Verify the company's ability to raise additional capital before Q4 2025 to avoid insolvency.
• Monitor the status of the Nasdaq deficiency notice and potential reverse stock split or delisting risks.
• Review the progress of the CLOVER-WaM confirmatory study discussions with the FDA.
• Assess the impact of the recent 60% workforce reduction on clinical trial timelines.
• Confirm the timeline for remediation of material weaknesses in internal financial controls.